← All trials
NCT05812755
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 19, 2023
- Primary completion
- Oct 31, 2026
- Completion date
- Nov 30, 2027
- First posted
- Apr 14, 2023
- Last posted
- Jul 6, 2023
- Enrollment
- 170
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vanderbilt UniversityLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Vanderbilt UniversityOverall official - principal investigator
- Vanderbilt UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.